Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a vaccine clear HPV after cervical lesion surgery?

NCT ID NCT06658405

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether giving the HPV vaccine to women over 45 who still have the virus after treatment for high-grade cervical lesions can help clear the virus faster. About 85 women will either get the vaccine or be observed without it. The goal is to see if the vaccine increases the chance of a negative HPV test within two years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 85 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2025

Expected to finish

Dec 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Common eligibility criteria for the study (for both cohorts) : 1. Female patient over 45 years old 2. Patient treated by conization for high-grade cervical epithelial lesion 3. Positive HPV test at the 6-month post-operative control (a delay of 6 to 12 months will be accepted), leading to an indication for a control colposcopy (+/- biopsy) according to standard surveillance practices. 4. N.B. : Patients with abnormalities at the initial control colposcopy and/or positive biopsy remain eligible for the study, whether vaccinated or not. 2. Additional eligibility criteria for the clinical trial (Vaccinated patients cohort) 1. No contraindication to HPV vaccination with Gardasil 9 2. Patient consented to HPV vaccination with Gardasil 9 3. Affiliated with a social security system 4. Informed and signed written consent provided 5. N.B. : Patients infected with HIV are eligible for the vaccine trial provided they are on antiretroviral therapy. 3. Inclusion criteria for the data study (Non-vaccinated patients cohort) 1. Patient eligible for the study (a) and not eligible for the clinical trial (b) due to: * refusal of vaccination, or * A contraindication to vaccination 2. No objection to the use of their personal data for research purposes N.B. : A patient who initially refused vaccination may later request to be vaccinated as part of the trial after signing the consent form. The vaccine trial analysis will include all patients who started vaccination within 6 months after the initial HPV control test. Exclusion Criteria: 1. Common exclusion criteria for the study (for both cohorts) 1. History of primary HPV vaccination 2. History of HPV-induced invasive cancer (cervical, vaginal, vulvar, anal, oropharyngeal cancer) 2. Exclusion criteria for the clinical trial (Vaccinated patients cohort) 1. Patient refusing HPV vaccination 2. Patient with a contraindication to HPV vaccination with Gardasil 9 3. Patient deprived of liberty or under guardianship 3. Exclusion criteria for the data study (Non-vaccinated patients cohort) a) Opposition to the use of their personal data for research purposes

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervical lesion are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Oscar Lambret

    RECRUITING

    Lille, 59020, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.